- Bone pain response via the Bone Pain Index Short Form (BPI-SF)
- Quality of life via the Functional Assessment of Cancer Therapy-Prostate (FACT-P)
- Disease progression
- Palliative radiotherapy requirement
- Analgesic advancements
- PSA and alkaline phosphatase progression
- Additional antineoplastic therapy
- ECOG performance status
- Overall survival
![PSA and alkaline phosphatase measures of disease progression AUA2018](/images/PSA_and_alkaline_phosphatase_measures_of_disease_progression_AUA2018.png)
Limitations of this study include the single arm design, non-randomization, open label and a relatively small sample size. However, the initial results demonstrate short term safety and tolerability among patients receiving concomitant Radium-223 and enzalutamide for men with symptomatic mCRPC. Important metrics such as improvement in pain scores, quality of life measures and maintenance of performance status were observed. A phase III randomized, prospective double arm trial (PEACE 3) comparing enzalutamide with Radium-223 vs enzalutamide alone is currently accruing patients.
References:
1. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369(3):213-223.
Presented by: Neal Shore, MD, FACS, Carolina Urologic Research Center, Myrtle Beach, SC
Co-Authors: Paul Schellhammer, Virginia Beach, VA, Ronald Tutrone, Towson, MD, Neil Mariados, Syracuse, NY, Stacey Harrelson, Myrtle Beach, SC
Written by: Zachary Klaassen, MD, Urologic Oncology Fellow, University of Toronto, Princess Margaret Cancer Centre at the 2018 AUA Annual Meeting - May 18 - 21, 2018 – San Francisco, CA USA